Gyre Therapeutics is trading at $4.08, down 7.66%, with no confirmed company-specific catalyst on November 5, 2026. - CNBC lists no recent news for Gyre Therapeutics; Q3 results are expected November 6. - The decline coincided with a sharp broader-market pullback, with the Nasdaq Composite down 3.23%. Biotech rose 2.05%, so sector weakness does not explain the move. - The specific cause remains unconfirmed.